Literature DB >> 20465500

ST2: a novel biomarker for heart failure.

Anju Bhardwaj1, James L Januzzi.   

Abstract

ST2, an IL-1 receptor family member with transmembrane (ST2L) and soluble (sST2) isoforms, was originally described in the context of inflammatory and autoimmune diseases. However, after the identification of IL-33 as the functional ligand for ST2, and conceptualization of the role of ST2/IL-33 signaling in cardiac remodeling, sST2 has emerged as a novel cardiovascular biomarker for the presence of ventricular biomechanical overload. Concentrations of sST2 have been implicated in the presence and severity of heart failure with particular value for prognostication. We will review the use of sST2 as a prognostic marker in heart failure, including present and future directions in this exciting area.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20465500     DOI: 10.1586/erm.10.25

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  25 in total

Review 1.  Clinical utility of antigen carbohydrate 125 in heart failure.

Authors:  Julio Núñez; Gema Miñana; Eduardo Núñez; Francisco J Chorro; Vicent Bodí; Juan Sanchis
Journal:  Heart Fail Rev       Date:  2014-09       Impact factor: 4.214

Review 2.  Novel Invasive and Noninvasive Cardiac-Specific Biomarkers in Obesity and Cardiovascular Diseases.

Authors:  Rajesh Parsanathan; Sushil K Jain
Journal:  Metab Syndr Relat Disord       Date:  2019-10-16       Impact factor: 1.894

3.  Cocaine use is associated with a higher prevalence of elevated ST2 concentrations.

Authors:  Xander M R van Wijk; Eric Vittinghoff; Alan H B Wu; Kara L Lynch; Elise D Riley
Journal:  Clin Biochem       Date:  2017-04-23       Impact factor: 3.281

4.  Effects of interleukin-33 on cardiac fibroblast gene expression and activity.

Authors:  Jinyu Zhu; Wayne Carver
Journal:  Cytokine       Date:  2012-03-23       Impact factor: 3.861

Review 5.  Meta-analyses of four eosinophil related gene variants in coronary heart disease.

Authors:  Jiangfang Lian; Yi Huang; R Stephanie Huang; Limin Xu; Yanping Le; Xi Yang; Weifeng Xu; Xiaoyan Huang; Meng Ye; Jianqing Zhou; Shiwei Duan
Journal:  J Thromb Thrombolysis       Date:  2013-11       Impact factor: 2.300

6.  Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study.

Authors:  Michael R Zile; Pardeep S Jhund; Catalin F Baicu; Brian L Claggett; Burkert Pieske; Adriaan A Voors; Margaret F Prescott; Victor Shi; Martin Lefkowitz; John J V McMurray; Scott D Solomon
Journal:  Circ Heart Fail       Date:  2016-01       Impact factor: 8.790

Review 7.  Secreted proteins as a fundamental source for biomarker discovery.

Authors:  Miroslava Stastna; Jennifer E Van Eyk
Journal:  Proteomics       Date:  2012-01-19       Impact factor: 3.984

Review 8.  Diagnosing destabilized heart failure in the emergency setting: current and future biomarker tests.

Authors:  Damien Gruson; Frédéric Thys; Franck Verschuren
Journal:  Mol Diagn Ther       Date:  2011-12-01       Impact factor: 4.074

Review 9.  Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction.

Authors:  Michael R Zile; Catalin F Baicu
Journal:  J Cardiovasc Transl Res       Date:  2013-05-29       Impact factor: 4.132

10.  The utility of biomarker risk prediction score in patients with chronic heart failure.

Authors:  Alexander E Berezin; Alexander A Kremzer; Yulia V Martovitskaya; Tatyana A Berezina; Tatyana A Samura
Journal:  Clin Hypertens       Date:  2016-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.